{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:39:40Z","timestamp":1773797980201,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National key projects of \u201c863\u201d High Technology","award":["2012AA02A401"],"award-info":[{"award-number":["2012AA02A401"]}]},{"name":"The Major National Science and Technology Projects","award":["2018ZX09201006"],"award-info":[{"award-number":["2018ZX09201006"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.03.038","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T00:28:49Z","timestamp":1521851329000},"page":"2450-2455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Japanese encephalitis virus\/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice"],"prefix":"10.1016","volume":"36","author":[{"given":"Huiqiang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhushi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianwu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2018.03.038_b0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.antiviral.2009.10.008","article-title":"Present and future arboviral threats","volume":"85","author":"Weaver","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.03.038_b0010","article-title":"Yellow fever burden estimation: summary","author":"Garske","year":"2013","journal-title":"WHO"},{"issue":"8","key":"10.1016\/j.vaccine.2018.03.038_b0015","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1089\/vbz.2016.2031","article-title":"Yellow fever remains a potential threat to public health","volume":"16","author":"Vasconcelos","year":"2016","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2018.03.038_b0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.03.038_b0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.03.038_b0030","first-page":"159","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J MedVirol"},{"issue":"14","key":"10.1016\/j.vaccine.2018.03.038_b0035","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.038_b0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/hv.22714","article-title":"Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more","volume":"9","author":"Miyaji","year":"2013","journal-title":"Hum Vacc Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.038_b0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/157488611797579258","article-title":"Reporting rates of yellow fever vaccine17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review","volume":"6","author":"Thomas","year":"2011","journal-title":"Curr Drug Saf"},{"issue":"9276","key":"10.1016\/j.vaccine.2018.03.038_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.03.038_b0055","unstructured":"WHO. Detection and investigation of serious adverse events following yellow fever vaccination; 18\u201319, November 2008."},{"issue":"14","key":"10.1016\/j.vaccine.2018.03.038_b0060","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J"},{"issue":"35","key":"10.1016\/j.vaccine.2018.03.038_b0065","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.03.038_b0070","doi-asserted-by":"crossref","first-page":"e0003693","DOI":"10.1371\/journal.pntd.0003693","article-title":"A DNA Vaccine against Yellow Fever Virus: Development and Evaluation","volume":"9","author":"Maciel","year":"2015","journal-title":"PLOS Neglected Trop Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.038_b0075","doi-asserted-by":"crossref","first-page":"e0004464","DOI":"10.1371\/journal.pntd.0004464","article-title":"Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus Infection in mice","volume":"10","author":"Bassi","year":"2016","journal-title":"PLOS Neglected Trop Dis"},{"key":"10.1016\/j.vaccine.2018.03.038_b0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virusres.2014.07.017","article-title":"Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone","volume":"191","author":"Li","year":"2014","journal-title":"Virus Res"},{"issue":"6","key":"10.1016\/j.vaccine.2018.03.038_b0085","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00705-016-2817-8","article-title":"A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone","volume":"161","author":"Yang","year":"2016","journal-title":"Arch Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.038_b0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13238-016-0363-5","article-title":"The chimeric Japanese encephalitis\/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus","volume":"8","author":"Yang","year":"2017","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.038_b0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.038_b0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40121-013-0018-2","article-title":"Japanese B encephalitis: an overview of the disease and use of chimerivax-JE as a preventative vaccine","volume":"2","author":"Chin","year":"2013","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2018.03.038_b0105","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.4161\/hv.29743","article-title":"A randomized study of the immunogenicity and safety of japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea","volume":"10","author":"Kim","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2018.03.038_b0110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14760584.2016.1189331","article-title":"The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection","volume":"15","author":"Pitisuttithum","year":"2016","journal-title":"Expert Rev Vacc"},{"issue":"5","key":"10.1016\/j.vaccine.2018.03.038_b0115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.vaccine.2011.12.034","article-title":"Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant","volume":"30","author":"Amorim","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.038_b0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.vaccine.2005.07.059","article-title":"Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non structural 1(NS1) gene fused to the tissue plasminogen activator signal sequence","volume":"24","author":"Costa","year":"2006","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2018.03.038_b0125","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/JVI.64.9.4356-4363.1990","article-title":"Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis","volume":"64","author":"Falgout","year":"1990","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.03.038_b0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/viro.1996.0406","article-title":"Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence","volume":"222","author":"Muylaert","year":"1996","journal-title":"Virology"},{"issue":"20","key":"10.1016\/j.vaccine.2018.03.038_b0135","article-title":"Envelope protein mutations L107F and E138K are important for neurovirulence attenuation for japanese encephalitis virus SA14-14-2 Strain","volume":"9","author":"Yang","year":"2017","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2018.03.038_b0140","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.03.038_b0145","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1080\/21645515.2015.1022700","article-title":"Serious adverse events associated with yellow fever vaccine","volume":"11","author":"de Menezes","year":"2015","journal-title":"Human Vacc Immunotherapeut"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T03:26:40Z","timestamp":1604028400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18303839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18303839"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Japanese encephalitis virus\/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}